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Background: Recent ﬁndings show that circulating N- and C-terminal fragments of IGF-binding protein-4
(NT-IGFBP-4 and CT-IGFBP-4) can be utilized as biomarkers for cardiac risk assessment in acute coronary syn-
drome (ACS) patients. The fragments are thought to be the products of pregnancy-associated plasma protein A
(PAPP-A)-dependent proteolysis. Two immunoassays for themeasurement of IGFBP-4 fragments have been pro-
posed. However, properties of the endogenous IGFBP-4 fragments that could inﬂuence the performance of the
immunoassays were still not investigated.
Methods: NT- and CT-IGFBP-4 were extracted from pooled ACS plasma using afﬁnity puriﬁcation, and their
concentrations were measured using sandwich immunoassays utilizing antibodies speciﬁc to their proteolytic
neo-epitopes or internal epitopes. The extracted fragments were characterized by Western blots (WB) and
mass-spectrometry. ACS plasma samples were analyzed by size exclusion chromatography (SEC).
Results: Immunoassays utilizing the neo-epitope-speciﬁc and the internal epitope-speciﬁc antibodies mea-
sured equal concentrations of the analyte in the endogenous IGFBP-4 fragments preparations. Only the 18 kDa
NT-IGFBP-4 and 14 kDa CT-IGFBP-4 were detected in the WB analysis. Using mass-spectrometry, peaks corre-
sponding to intact non-truncated and non-modiﬁed NT-IGFBP-4 (14626 Da) and CT-IGFBP-4 (11346 Da) were
observed. The absence of complexed forms of IGFBP-4 in patients' plasma was demonstrated using SEC.
Conclusions: Endogenous NT- and CT-IGFBP-4 from ACS patients' plasma correspond to the PAPP-A-derived
IGFBP-4 fragments and do not undergo any truncation,modiﬁcation, or complex formation in the patients' blood.
Because of the demonstrated intact state of the circulating IGFBP-4 fragments, the neo-epitope-speciﬁc immuno-
assays perform reliably, allowing further clinical validation of these novel biomarkers.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Major adverse cardiac events (MACE) associated with atherosclero-
sis are some of the most daunting problems in current clinical practice
and diagnostics. Intense development of new approaches for risk as-
sessment of plaque destabilization has resulted in numerous molecules
that have been analyzed and described as candidate predictive bio-
markers for MACE [1]. One of these candidates is the zinc metallopro-
teinase pregnancy-associated plasma protein A (PAPP-A).
In 2001, Bayes-Genis et al. suggested that PAPP-A could act as a
marker of atherosclerotic plaque destabilization [2]. It was shown thatu 6, Turku, Finland. Fax: +358
iety of Clinical Chemists. PublisPAPP-A is overexpressed in unstable atherosclerotic plaques, and in-
creased levels of an acute coronary syndrome (ACS)-speciﬁc dimeric
form of PAPP-A (dPAPP-A) can be detected in patients' blood aftermyo-
cardial infarction (MI) [3,4]. However, it is now clear that dPAPP-A as-
says have limitations and technical difﬁculties related to: i) extremely
low concentration in the plasma, ii) a relatively high proportion of
PAPP-A in the inactive form [5], and iii) changes in the blood PAPP-A
levels caused by heparin administration [6,7].
Due to these difﬁculties, we have proposed a new approach that is
based on measurement of the products of PAPP-A-dependent proteoly-
sis in the blood. PAPP-A was shown as the only known protease that is
able to cleave IGF-binding protein-4 (IGFBP-4) between Met-135 and
Lys-136 [8–13]. The high speciﬁcity of this cleavage is conferred bymul-
tiple PAPP-A-IGFBP-4 interaction sites [14,15]. The cleavage results in
two IGFBP-4 fragments: NT-IGFBP-4 (amino acids 1–135, 14 628 Da)
and CT-IGFBP-4 (amino acids 136–237, 11 345 Da).hed by Elsevier Inc. This is an open access article under the CC BY license
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been shown to be active and capable of cleaving IGFBP-4 [16]. We pro-
pose that the concentration of the products of IGFBP-4 cleavage by
PAPP-A (NT-IGFBP-4 and CT-IGFBP-4) in patients' blood reﬂects the
level of dPAPP-A enzymatic activity in plaques, thus reporting on the
degree of plaque instability.
Recently, we have shown that both NT- and CT-IGFBP-4 appear to be
strong short-term predictors of MACE in patients with myocardial is-
chemia symptoms. The risk of MACE was approximately 14 times
higher for patients with NT-IGFBP-4 levels ≥ 214 μg/L and approximate-
ly 8 times higher for patients with CT-IGFBP-4 levels ≥ 124 μg/L [17]. In
another report, CT-IGFBP-4 was correlated to the presence of coronary
artery disease and B-type coronary lesions in patients with stable car-
diovascular disease [18].
Two sandwich immunoassays designed for NT- and CT-IGFBP-4
quantiﬁcation have been previously described [17]. In each assay, one
of the antibodies is speciﬁc to the neo-epitope, formed by IGFBP-4
cleavage by PAPP-A into NT- or CT-IGFBP-4. Namely, IBP3 is speciﬁc to
NT-IGFBP-4 proteolytic neo-epitope, whereas IBP163 is speciﬁc to
CT-IGFBP-4 proteolytic neo-epitope. The epitopes of these antibodies
should include the terminal amino acid residues (a.a.r., Met-135 and
Lys-136, respectively) and some adjacent residues. These antibodies
are speciﬁc only to NT- and CT-IGFBP-4 with less than 1.5% of cross-
reactivity to full-length IGFBP-4. As a result, these assays are
fragment-speciﬁc.
Accuratemeasurement of the analyte in the sample is dependent on
the ability of the assay antibodies to recognize all clinically relevant
forms of the analyte. In the case of the IGFBP-4 fragments, onemight ex-
pect to ﬁnd them partially truncated, glycosylated, or in complex with
other proteins. For diagnostic use of the IGFBP-4 fragment immunoas-
says, it is necessary to show that such modiﬁcations do not affect the
measurements. Thus, the major goal of the study was to characterize
the endogenously circulating IGFBP-4 fragments and investigatewheth-
er modiﬁcations of the fragments would inﬂuence the performance of
the IGFBP-4 fragment-speciﬁc immunoassays.
2. Materials and methods
2.1. Monoclonal antibodies, recombinant proteins, and peptides
All of the monoclonal antibodies (MAbs) and recombinant IGFBP-4,
NT-IGFBP-4 and CT-IGFBP-4 used in this studywere provided by HyTest
Ltd, Finland. Recombinant proteinswere expressed inmammalian cells.
Peptides NT0, NT1, NT2, NT3, and CT0, CT1, CT2, CT3 were synthesized
by Peptide 2.0, USA.
2.2. Characterization of anti-NT-IGFBP-4 and anti-CT-IGFBP-4 MAbs
To analyze the sensitivity of neo-epitope-speciﬁc antibodies (MAbs
IBP3 and IBP163) to the stepwise neo-epitope truncation, a set of pep-
tides NT0-NT3 and CT0-CT3 was used (see Table 1). Peptides NT0 and
CT0 represent the C-terminal part of NT-IGFBP-4 and N-terminal part
of CT-IGFBP-4, respectively, whereas NT1-NT3 and CT1-CT3 were
shorter peptides consecutively missing 1, 2, or 3 amino acid residuesTable 1
Synthetic peptides used for MAbs IBP3 and IBP163 epitope mapping.
Peptide Sequence
NT0 C-H121FAKIRDRSTSGGKM135
NT1 C-H121FAKIRDRSTSGGK134
NT2 C-H121FAKIRDRSTSGG133
NT3 C-H121FAKIRDRSTSG132
CT0 K136VNGAPREDARPVPQ150-C
CT1 V137NGAPREDARPVPQ150-C
CT2 N138GAPREDARPVPQ150-C
CT3 G139APREDARPVPQ150-Cfrom C-terminus (if compared with NT0), or from N-terminus (if com-
pared with CT0).
Each peptide contained an additional terminal cysteine residue for
coupling the peptide to a carrier protein (BSA, Sigma, USA) using
succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (Pierce,
USA) according to the manufacturer's instructions.
The immunoreactivity of each BSA-peptide conjugate was tested
using a direct immunoassay. BSA-peptide conjugates were sorbed
onto polystyrene plates (10 ng/well) and incubatedwith the conjugates
of MAbs IBP3 and IBP163 with a stable Eu3+-chelate prepared as de-
scribed by Katrukha et al. [19]. Fluorescence of Eu3+ was measured as
described by Tamm et al. [20].
2.3. Blood samples
The study was performed in accordance with the current revision of
the Helsinki Declaration. The Clinical Research Ethics Committee of
Moscow City Hospital #67 (Russian Federation) approved the study.
EDTA-treated plasma samples from 33 ACS patients were obtained
to extract IGFBP-4 proteolytic fragments (Table 2). Inclusion criteria
were diagnosed unstable angina or STEMI. Blood samples were obtain-
ed at the time of presentation at the hospital emergency department
(60–300 min after symptom onset).
2.4. Afﬁnity extraction of the endogenous NT-IGFBP-4 and CT-IGFBP-4
Collected EDTA-treated plasma samples from ACS patients were
pooled, and endogenous IGFBP-4, NT-IGFBP-4, and CT-IGFBP-4were ex-
tracted by afﬁnity chromatography.
Two columns with Sepharose CL-4B (Pharmacia, USA) having either
immobilized MAb IBP180 speciﬁc to the N-terminal part of IGFBP-4
(immunosorbent-IBP180) or MAb IBP185 speciﬁc to C-terminal part of
IGFBP-4 (immunosorbent-IBP185) were equilibrated with 20 mM Tris–
HCl, 150 mM NaCl, pH 7.4. After centrifugation (10000 g, 10 min,
+4 °C), plasma was loaded onto the column containing immuno-
sorbent-IBP180. The column was washed by buffer containing 20 mM
Tris–HCl, 750 mM NaCl, pH 7.4, and the mixture of NT-IGFBP-4 and
full-length IGFBP-4was eluted using 100mMGlycine-HCl, pH 2.5. To re-
move full-length IGFBP-4, the eluate neutralized with 2 M Tris base was
run over the column containing immunosorbent-IBP185. The ﬂow-
through contained the NT-IGFBP-4. NT-IGFBP-4/IGFBP-4 free plasma ob-
tained after NT-IGFBP-4 extractionwas loaded onto the column contain-
ing immunosorbent-IBP185, and CT-IGFBP-4 was eluted using 100 mM
Glycine-HCl, pH 2.5. The eluate was then neutralized with 2 M Tris base.
To determine if there were any form of CT-IGFBP-4 with a truncated
C-terminus, two additional afﬁnity columns were used: one containing
afﬁnity matrix with immobilized MAb IBP190 that is speciﬁc to the
N-terminal part of CT-IGFBP-4 (immunosorbent-IBP190) and another
one with MAb IBP163 (speciﬁc to the CT-IGFBP-4 neo-epitope;
immunosorbent-IBP163).
The yield of NT-IGFBP-4 afﬁnity extraction on the immunosorbent-
IBP180 was 84.3%. The yield of CT-IGFBP-4 afﬁnity extraction was
97.0, 85.8, and 89.3% for the immunosorbent-IBP185, -IBP190, and
-IBP163, respectively.Table 2
Baseline characteristics of patients group. Values are presented as mean ±
SD. Dichotomous variables are indicated as number (n) of total patients.
Characteristics Patients (n = 33)
Age (years) 73.6 ± 10.6
Males/females (n) 14/19
Instable angina (n) 14
STEMI (n) 19
Diabetes mellitus (n) 5
Creatinine (μmol/L) 107.7 ± 25.6
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Extracted NT-IGFBP-4 and CT-IGFBP-4 electrophoresed in a 10–20%
gradient polyacrylamide gel using a Tris-Glycine buffer systemwith so-
dium dodecyl sulfate and 2-mercaptoethanol and blotted onto a nitro-
cellulose membrane. 20 mM KH2PO4, 150 mM NaCl, pH 7.4, 0.01%
Tween 20 (PBST) containing 1% dry milk was used for membrane
blocking (15 min at room temperature). Then themembrane was incu-
bated for 60 min at room temperature with anti-IGFBP-4 MAbs at
10 μg/mL in PBST. The membrane was washed and incubated with
goat anti-mouse IgG polyclonal secondary antibodies conjugated with
horseradish peroxidase (Sigma, USA) at 1 μg/mL for 30 min at room
temperature. Staining was performed using 3,3′-diaminobenzidine
tetrahydrochloride (Sigma, USA).
2.6. Mass-spectrometry (MS) study
The samples containing IGFBP-4 or its proteolytic fragments
(0.1–1.0 μg in 50% acetonitrile with 0.1% triﬂuoroacetic acid (Aldrich,
Germany)) were prepared using ZipTip C18 pipette tips (Millipore,
USA). The sample (0.5 μL) was mixed with the equal volume of
2,5-dihydroxybenzoic acid (Aldrich, Germany, 10 mg/mL in 20% aceto-
nitrile with 0.5% TFA) on the target plate. An UltraﬂeXtreme MALDI
TOF/TOF mass-spectrometer (Bruker Daltonics, Germany) with an UV-
laser (Nd) in positive ions mode was used for the analysis. The spectra
were detected across a mass range of 2000 to 35000m/z with accuracy
of b 0.05%.
2.7. Size-exclusion chromatography (SEC)
Pooled ACS plasma samples were separated on a Superdex 75 10/
300 GL column (GE Healthcare, USA). 0.2 mL plasma samples were
centrifuged (10000 g, 10 min, +4 °C) and then loaded onto a column
equilibrated with 20 mM KH2PO4, 150 mM NaCl, pH 7.4 (PBS). Recom-
binant IGFBP-4, NT-IGFBP-4, and CT-IGFBP-4 were used as standards.
The collected fractions (0.2 mL each) were tested for full-length
IGFBP-4 and NT- and CT-IGFBP-4 fragments using the sandwich
immunoassays.Fig. 1. Scheme of the antibody epitopes and sandwich immunoassays for the IGFBP-4 molec
121–135) and IBP163 (a.a.r. 136–150). The regions containing the internal epitopes are sho
108–122), IBP17 (a.a.r. 126–133), IBP190 (a.a.r. 137–142), IBP151 (a.a.r. 142–150), IBP182 (a.a.r
by an arrow.2.8. Sandwich immunoassays
IGFBP-4 and its fragments were measured using neo- and internal
epitope-speciﬁc sandwich immunoassays (see Fig. 1). Full-length
IGFBP-4 was measured using the IBP185-IBP154Eu (capture MAb-
detection MAb) immunoassay. NT-IGFBP-4 and CT-IGFBP-4 were
measured using the IBP3-IBP180Eu and IBP182-IBP163Eu immunoas-
says, respectively. The IBP17-IBP180Eu assay was used to quantify both
full-length IGFBP-4 and NT-IGFBP-4. The IBP185-IBP151Eu assay was
used to quantify both full-length IGFBP-4 and CT-IGFBP-4.
Capture MAbs (20 μg/mL, 0.1 mL/well in PBS) were incubated in a
96-well polystyrene plate for 30 min at room temperature with con-
stant shaking. The plate was then washed with 10 mM Tris–HCl, pH
7.8, supplemented with 150 mM NaCl, 0.025% Tween 20, and 0.05%
NaN3 (buffer A). 0.05 mL of the sample diluted in assay buffer (50 mM
Tris–HCl buffer, pH 7.7, 0.9% NaCl, 0.01% Tween 40, 0.5% BSA, 0.05%
NaN3), and 0.05 mL of the detection antibodies (4 μg/mL) were added
to the plate. Recombinant NT-IGFBP-4, CT-IGFBP-4, and IGFBP-4 were
used for calibration of corresponding assays. Plates were incubated for
30 min at room temperature with constant shaking.
After washing with buffer A, 0.2 mL per well of enhancement solu-
tion was added and ﬂuorescence of Eu3+ was measured as described
by Tamm et al. [20].
3. Results
3.1. Speciﬁcity of anti-NT-IGFBP-4 and anti-CT-IGFBP-4 MAbs
Using peptides NT0-NT3 and CT0-CT3, we showed that the neo-
epitope-speciﬁc MAbs IBP3 and IBP163 do not react with truncated
forms of the IGFBP-4 fragments. The removal of even one terminal
a.a.r. from C-terminus for NT0 and from N-terminus for CT0 leads to a
decrease in the immunoreactivity down to 1% of the immunoreactivity
obtained with the non-truncated peptide.
3.2. Extraction of endogenous NT-IGFBP-4 and CT-IGFBP-4
Endogenous IGFBP-4 fragments were extracted using afﬁnity chro-
matography for further characterization of their properties. Both afﬁnityules. The regions containing the neo-epitopes are shown as grey bars: MAbs IBP3 (a.a.r.
wn as white bars: MAbs IBP144 (a.a.r. 108–127), IBP180 (a.a.r. 108–122), IBP154 (a.a.r.
. 222–236), and IBP185 (a.a.r. 222–236). The cleavage site of IGFBP-4by PAPP-A is indicated
Fig. 2. Western blotting of recombinant and endogenous NT-IGFBP-4 and CT-IGFBP-4.
Lane 1—molecular mass standards. NT-IGFBP-4 was detected by MAbs IBP144 (lanes 2
and 3), IBP3 (lane 4); CT-IGFBP-4 was detected by MAbs IBP185 (lanes 5 and 6), IBP163
(lane 7).
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or CT-IGFBP-4 immunoreactivity was detected in plasma after the
extraction (as measured by IBP3-IBP180Eu and IBP182-IBP163Eu assays,
respectively). This result indicates that all forms of the IGFBP-4
fragments that can be detected by the neo-epitope-speciﬁc assays
were successfully extracted.
3.3. Investigation of truncation of endogenous NT-IGFBP-4 and CT-IGFBP-4
The concentrations of afﬁnity puriﬁed NT-IGFBP-4 and CT-IGFBP-4
were measured utilizing internal epitope-speciﬁc reference assays
(IBP17-IBP180Eu and IBP185-IBP151Eu, respectively) and neo-epitope-
speciﬁc assays (IBP3-IBP180Eu and IBP182-IBP163Eu, respectively).
Both measurements gave very similar results—103.5% of NT-IGFBP4
and 92.9% of CT-IGFBP-4 weremeasured by neo-epitope-speciﬁc assays
if compared with results of measurements by reference assays.Fig. 3. Mass-spectra of endogenous NT-IGFBP-4 and CT-IGFBP-4. A—NT-IGFBP-4 extracted
C—CT-IGFBP-4 extracted with immunosorbent-IBP190; D—CT-IGFBP-4 extracted with neo-epitAs was shown byWestern blotting, both afﬁnity puriﬁed NT-IGFBP-
4 and CT-IGFBP4 displayed the apparent molecular masses equal to
their recombinant analogues (18 and 14 kDa, respectively, Fig. 2).
Only one protein band was present for both endogenous fragments
with no additional bands of higher or lower masses.
Data obtained byWestern blottingwere conﬁrmed byMS analysis of
the endogenous NT-IGFBP-4 and CT-IGFBP-4. The MS studies of the en-
dogenous IGFBP-4 fragments extracted using the immunosorbent-
IBP180 (for NT-IGFBP-4) and immunosorbent-IBP185 (for CT-IGFBP-4)
revealed the only one peak for each protein corresponding to the prod-
ucts of PAPP-A-dependent cleavage of full-length IGFBP-4 (14626 and
11346 Da, respectively; Fig. 3A, B). Themolecularmasses of the puriﬁed
NT-IGFBP-4 and CT-IGFBP-4 were similar to their theoretic masses
(14628 and 11345 Da, respectively). No peaks corresponding to any
truncated forms of NT-IGFBP-4 or CT-IGFBP-4 were detected. Endoge-
nous CT-IGFBP-4 puriﬁed with the other immunosorbent-IBP190 that
was speciﬁc to N-terminus of CT-IGFBP-4 also had a molecular mass
very close to its theoretic mass (11347 Da, Fig. 3C). No other peaks cor-
responding to truncated CT-IGFBP-4 were also detected in this case. A
very similar result was obtained using the neo-epitope-speciﬁc
immunosorbent-IBP163. In this case, the mass-spectrum of CT-IGFBP-
4 had a peak corresponding to the intact form of CT-IGFBP-4
(11351 Da), and no peaks corresponding to truncated forms of CT-
IGFBP-4 (Fig. 3D).
3.4. SEC studies of IGFBP-4 and its fragments in ACS plasma
NT-IGFBP-4, CT-IGFBP-4, and full-length IGFBP-4 measurements in
fractions after plasma protein separation by SEC revealed 3 main
peaks corresponding to the three forms of IGFBP-4: 13.1 kDa
(CT-IGFBP-4), 18.0 kDa (NT-IGFBP-4), and 26.9 kDa (IGFBP-4, Fig. 4).
Three corresponding recombinant standards spiked into IGFBP-4 free
plasma displayed the same mobility as the endogenous proteins.
4. Discussion
In our recent study, we have reported new immunoassays for quan-
titative measurement of NT-IGFBP-4 and CT-IGFBP-4 [17]. We have
shown that these assays could be used to measure IGFBP-4 fragments
in healthy donors and in patients with symptoms of myocardial ische-
mia. We proposed the use of NT-IGFBP-4 and CT-IGFBP-4 as the bio-
markers for short-term prediction of MACE in patients presenting
with myocardial ischemia symptoms.
In this study, we extracted and characterized NT-IGFBP-4 and
CT-IGFBP-4 from ACS patients' plasma for the ﬁrst time. In addition,
our data on the detailed epitope speciﬁcity of MAbs IBP3 and IBP163
support the idea of using recently described immunoassays for thewith immunosorbent-IBP180. B—CT-IGFBP-4 extracted with immunosorbent-IBP185;
ope-speciﬁc immunosorbent-IBP163.
Fig. 4. Endogenous IGFBP-4, NT-IGFBP-4, and CT-IGFBP-4 distribution in fractions obtained by SEC of the pooled ACS plasma (Superdex 75 10/300 column).
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reports on IGFBP-4 and its cleavage into fragments have been published
[8,14,15,21]. However, themain subject of these studieswas the proteo-
lytic properties of PAPP-A, whereas NT-IGFBP-4 and CT-IGFBP-4 were
considered as the proteolytic reaction byproducts. Endogenous IGFBP-
4 fragments were also described in the studies by Standker et al. [22,
23] in connection with renal dysfunction.
In our previous report, we describedMAbs IBP3 and IBP163 as being
speciﬁc to NT-IGFBP-4 and CT-IGFBP-4, respectively, and with no cross-
reactivity with full-length IGFBP-4 [17], which is present in the blood at
an approximately equal or even higher concentration than NT-IGFBP-4
or CT-IGFBP-4 [24–26]. MAbs IBP3 and IBP163 are speciﬁc to the neo-
epitopes that are located at the C-terminus of NT-IGFBP-4 and at the
N-terminus of CT-IGFBP-4, which are formed after IGFBP-4 cleavage
by PAPP-A. However, the inﬂuence of the degradation of the neo-
epitopes to the reactivity of these MAbs was unstudied. Utilizing a set
of truncated peptides, we showed that neo-epitope-speciﬁc MAbs
IBP3 and IBP163 interact only with non-truncated NT-IGFBP-4 and
CT-IGFBP-4, respectively. Any truncated forms of NT-IGFBP-4 and
CT-IGFBP-4 cannot be detected. Therefore, our sandwich immunoassays
(IBP3-IBP180Eu and IBP182-IBP163Eu for NT-IGFBP-4 and CT-IGFBP-4,
respectively) detect only the IGFBP-4 fragments containing intact neo-
epitopes. In other words, both immunoassays can detect only
NT-IGFBP-4 and CT-IGFBP-4 that are formed by PAPP-A-dependent
IGFBP-4 cleavage that occurs between Met-135 and Lys-136. It is well
known that proteolytic truncation of two or even one terminal a.a.r.
may lead to a loss of immunoreactivity of some protein if the antibody
used in the immunoassay is speciﬁc to the very end of its terminal
region. For example, some anti-B-type natriuretic peptide (BNP)
sandwich immunoassays cannot detect BNP if it loses 1–2 a.a.r. at the
C-terminus [27,28].
Because our immunoassays are highly susceptible to IGFBP-4 frag-
ment terminal truncation, we investigated potential degradation of
NT-IGFBP-4 and CT-IGFBP-4 in patients' plasma. To detect all possible
forms of IGFBP-4 proteolytic fragments in ACS plasma, the afﬁnity puri-
ﬁcations of these proteins were performed using the immunosorbents
speciﬁc to different epitopes.
To study the state of the extracted NT-IGFBP-4 and CT-IGFBP-4 neo-
epitopes, we compared the concentrations measured in different sand-
wich immunoassays utilizing the recombinant analogues as calibrators.
NT-IGFBP-4 and CT-IGFBP-4 concentrations measured in neo-epitope-
speciﬁc assays (IBP3-IBP180Eu and IBP182-IBP163Eu, respectively)
were similar to the concentrations measured in the reference assays
(speciﬁc to internal epitopes of the fragments). If any fraction of the
NT-IGFBP-4 and CT-IGFBP-4 molecules contained truncated neo-epitopes, the concentrations of the extracted proteins measured in the
reference assays would be higher than the concentrations measured in
the neo-epitope-speciﬁc assays. We did not observe these differences,
suggesting that NT-IGFBP-4 and CT-IGFBP-4 molecules with truncated
neo-epitopes in ACS plasma are absent or at negligible concentrations.
It is important to note that endogenous and recombinant IGFBP-4
fragments demonstrate similar immunochemical properties in the
neo-epitope-speciﬁc assays. Thus, we can conclude that both recombi-
nant analogues of NT-IGFBP-4 and CT-IGFBP-4 selected for this study
could be used as calibrators for the corresponding immunoassay.
According to the Western blots, the extracted NT-IGFBP-4 and
CT-IGFBP-4 have the expectedmolecularweight for the IGFBP-4 proteo-
lytic fragments formed by PAPP-A-dependent cleavage (18 and 14 kDa,
respectively, Fig. 2). They also have molecular weights that match the
recombinant NT-IGFBP-4 and CT-IGFBP-4. The obtained endogenous
proteins were detected using MAbs speciﬁc to the internal parts of the
molecules (IBP144, IBP185) and to the neo-epitopes (IBP3, IBP163).
These data suggest that extracted NT-IGFBP-4 and CT-IGFBP-4 contain
intact neo-epitopes that are most likely linear.
At the outset of this study, we expected to see multiple forms of en-
dogenous NT-IGFBP-4 and CT-IGFBP-4 of varying molecular mass. The
diversity of IGFBP-4 forms can be generated not only by truncation of
NT-IGFBP-4 and CT-IGFBP-4 neo-epitopes but also by partial cleavage
of full-length IGFBP-4. NT-IGFBP-41–122 was previously found in the
hemoﬁltrate of patients suffering from chronic renal disease [22].
However, we did not see bands with lower molecular masses than the
original fragments in our Western blots of the puriﬁed NT-IGFBP-4
and CT-IGFBP-4. For NT-IGFBP-41–122 in human blood, we can speculate
that the fragment was found in the hemoﬁltrate of patients with renal
dysfunction, which may not be appropriate to compare with these
data using plasma from ACS patients. Notably, the NT-IGFBP-41–122 ex-
traction method by Standker et al. was multi-step [22] and could itself
lead to NT-IGFBP-4 degradation.
The results of Western blotting and immunoassay analysis showing
that there are no truncated forms of IGFBP-4 fragments in patients'
blood were conﬁrmed by MS analysis. The MS study of endogenous
NT-IGFBP-4 preparation obtained with immunosorbent-IBP180 re-
vealed only one peak corresponding to NT-IGFBP-41–135 (14626 Da,
theoretical mass 14628 Da). The spectrum did not display any peaks
corresponding to truncated forms of endogenous NT-IGFBP-4.
Three different preparations of endogenous CT-IGFBP-4 obtained
using immunosorbent-IBP163, -IBP185, and -IBP190 were used for MS
study. These immunosorbents are speciﬁc to different epitopes of the
CT-IGFBP-4 molecule (Fig. 1) and allow for extraction of CT-IGFBP-4
forms that are potentially truncated at the N- or C-terminus. All three
779A.A. Konev et al. / Clinical Biochemistry 48 (2015) 774–780mass-spectra display only one peak corresponding to intact CT-IGFBP-4
(theoretical molecularmass 11351Da) at 11351, 11346, and 11347 Da,
respectively.
Another possible source of IGFBP-4 diversity is posttranslational
modiﬁcation of the protein. Asn-104 was described as the site of
IGFBP-4 glycosylation [29]. The presumably glycosylated residue Asn-
104 is located in NT-IGFBP-4 after PAPP-A-dependent cleavage of
IGFBP-4; however, the MS studies did not show any peaks that could
be attributed to the N-glycosylated forms of NT-IGFBP-4. The IGFBP-4
cleavage site between Met-135 and Lys-136 is rather distant from
Asn-104; however, it is well known that the speciﬁcity of interactions
of PAPP-A and IGFBP-4 is dependent on multiple interaction sites [15]
and that substrate residues distant from the scissile bond are critical
for proteolysis [14]. The glycosylation of Asn-104 can potentially dam-
age these interactions, and it is possible that PAPP-A-dependent prote-
olysis of glycosylated IGFBP-4 is suppressed. A similar phenomenon
has been described on proteolysis-dependent BNP precursor (proBNP)
processing, which is blocked by glycosylation of the amino acid residues
located close to the cleavage site [30]. However, in contrast to previous-
ly reported data, we showed that the plasma of ACS patients does not
contain any truncated or posttranslationally modiﬁed forms of both
NT- and CT-IGFBP-4 fragments.
Other than degradation or modiﬁcation of IGFBP-4 fragments, po-
tential formation of complexes of the fragments with any proteins in
the plasma can inﬂuence the epitopes' availability for speciﬁc binding
in the sandwich immunoassay (i.e., epitope masking). It is well known
that the proteins of the IGFBP family IGFBP-3 and IGFBP-5 form a terna-
ry complex with the 85-kDa acid labile subunit (ALS glycoprotein) in
plasma [31,32]. IGF binding was described not only for full-length
IGFBP-4 but also for NT-IGFBP-4 [22,33]. CT-IGFBP-4-heparin interac-
tions were also described [34]. Performing SEC studies of patients'
blood samples, we expected to ﬁnd multiple forms with different
molecular masses, displaying IGFBP-4 immunoreactivity. However,
after plasma protein separation by SEC, we observed the immunoreac-
tivity peaks corresponding to IGFBP-4, NT-IGFBP-4, and CT-IGFBP-4
only. No higher molecular weight peaks were detected, suggesting
that IGFBP-4 and its fragments are mainly presented in plasma as
non-complexed molecules.
4.1. Limitations
A set of anti-IGFBP-4 MAbs interacting with epitopes that cover the
entire amino acid sequence of IGFBP-4 molecule is not available (see
Fig. 1). Thus, our ability to extract diverse forms of endogenous IGFBP-
4 fragments is limited by the polypeptides that form epitopes of the
MAbs used in this study. Additionally, it should be noted that i) ACS pa-
tients are a very broadgroupwhich includes in our study the individuals
with unstable angina and STEMI, ii) the different timing of specimen
sampling may inﬂuence the diversity of NT- and CT-IGFBP-4 forms,
and iii) the extraction of IGFBP-4 fragments from pooled ACS plasma
may not reﬂect the diversity of individual's proﬁle of IGFBP-4 forms.
5. Conclusions
The presence of NT-IGFBP-41–135 and CT-IGFBP-4136–237 fragments
in human ACS plasma was shown. It conforms to the hypothesis that
IGFBP-4 fragments detected in ACS patients' plasma are derived from
IGFBP-4 during PAPP-A-dependent cleavage. However, the suggestion
that PAPP-A cleaves IGFBP-4 in unstable atherosclerotic plaque is, as
yet, not directly shown.
The absence of NT-IGFBP-4 and CT-IGFBP-4neo-epitope degradation
in ACS patients' blood aswell as the absence of complex formation with
plasma proteins were demonstrated. The possibility of truncation of
NT-IGFBP-4 and CT-IGFBP-4 in ACS plasma would be a serious problem
for the fragment detection because of the neo-epitope-speciﬁc immu-
noassays' (IBP3-IBP180Eu and IBP182-IBP163Eu) high susceptibility toneo-epitope degradation. Thus, absence of proteolytic degradation of
IGFBP-4 fragments in ACS plasma supports the reliable measurement
of the fragments by the neo-epitope-speciﬁc immunoassays.
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